SHR-A1811 for Injection
Sponsors
Henan Cancer Hospital, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions
Early-stage or Locally Advanced HER2-positive Breast CancerGastric CancerGastroesophageal-junction CancerHER2 Low Breast CarcinomaPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerSolid TumorSolid Tumors
Phase 1
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
RecruitingNCT07231211
Start: 2025-11-20End: 2027-12-01Target: 258Updated: 2026-09-10
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
RecruitingNCT07275242
Start: 2025-12-23End: 2027-12-31Target: 107Updated: 2026-01-15
Phase 2
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
RecruitingNCT05911958
Start: 2023-07-05End: 2029-05-31Target: 66Updated: 2024-11-04
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
RecruitingNCT07110571
Start: 2025-08-28End: 2027-05-31Target: 200Updated: 2026-01-09
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
RecruitingNCT07111832
Start: 2025-08-20End: 2028-12-31Target: 400Updated: 2025-12-18
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Active, not recruitingNCT07196774
Start: 2025-10-23End: 2028-12-01Updated: 2026-07-30